- Company may target raising more than $250 million in an IPO
- US listings for drug developers raised $3.2 billion this year
Rivus Pharmaceuticals Inc., a drug developer focused on obesity treatments, is considering a US initial public offering as soon as 2024, according to people with knowledge of the matter.
The company is working with banks on a listing, said the people, who asked not to be identified because they weren’t authorized to speak publicly. Rivus, which counts RA Capital Management among its investors, may target raising more than $250 million, one of the people said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.